Home MarketIpca Laboratories Ltd.

Ipca Laboratories Ltd. Stock Info: As on 2018-02-16 15:58:05

Nse

626.50

25.45(4.23%)
Change%
52 Week Range
400.00
11.00
657.60
5.00
Open606.45
Day's Range480.84 - 721.26
Value Traded (in ₹ Cr.) 19.49

Bse

625.25

21.60(3.58%)
Change %
52 Week Range
400.00
11.00
656.00
5.00
Open619.00
Day's Range482.92 - 724.38
Value Traded (in ₹ Cr.) 1.22

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 58,216,236.00 46.13%
Mutual Funds/UTI 29,301,667.00 23.22%
FII 17,529,591.00 13.89%
Employee 0.00 0.00%
Public 13,141,856.00 10.41%
Government 102,185.00 0.08%
Others 5,021,011.00 3.98%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 2.60
Basic EPS (Rs.) 7.25
Cash EPS 20.69
BVPerShare Excl 182.73
Operating Revenue 223.13
PBDITPerShare 24.40
Dividend 0.00
NPPerShare 7.25
Current Ratio 1.82
Quick Ratio 0.82
PriceToBV 3.17
Earnings 0.01
PBDIT Margin 10.93
PBT Margin 3.85
NP Margin 3.24
Return On Assets 2.39
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,838.92
Total Expenses 2,730.40
EBITDA 307.91
PBT 108.52
PAT 91.45
Net Income 91.45
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,322.34
Total Expenses 1,239.92
EBITDA -1.55
PBT 61.49
PAT 60.87
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 25.24
Net worth 2,306.09
Investments 96.47
Total Liability 3,822.84
Total debt 595.01
Net block 2,097.02
Total Assets 3,822.84
Parameter Sep-16 (₹ Cr.) 6M % change
Total share capital 25.24
Net worth 2,247.78
Investments 142.42
Total Liability 3,862.28
Total debt 854.70
Net block 2,080.22
Total Assets 3,862.28
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

648.8 655.8 -1.07
611680

Abbott India Ltd.

5518.15 5652.6 -2.38
5470.056159

Ajanta Pharma Ltd.

1391.75 1408 -1.15
13771446.95

Albert David Ltd.

384.15 390.6 -1.65
378410.85

Alembic Ltd.

61.05 62.35 -2.09
60.765

Alembic Pharmaceuticals Ltd.

576.45 577.15 -0.12
546.55589.4

Alkem Laboratories Ltd.

2164.4 2132.4 1.5
2115.12200.05
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

51.7 53.9 -4.08
50.7557.55

Aarti Drugs Ltd.

650 656 -0.91
614680

Aayush Food & Herbs Ltd.

62.65 66.05 -5.15
61.680.35

Abbott India Ltd.

5675 5633.45 0.74
55006109.95

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 485.09
Cash from investing activities -202.90
Cash from financing activities -213.96
Net change in cash 68.23

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
HDFC Mid-Cap Opportunities Fund - Regular Plan 1.06%
ICICI Prudential Long Term Equity Fund 2.97%
DSP BlackRock Micro-Cap Fund 2.22%
Franklin India Smaller Companies Fund 1.57%
DSP BlackRock Small And Mid Cap Fund 2.15%
Mirae Asset Emerging Bluechip Fund 1.58%

KDDL Q3 net profit zooms 200.71% at Rs 4.21 cr

The company reported standalone net profit of Rs 4.21 crore for the quarter ended December 31, 2017 as compared to Rs 1.40 crore in the same period last year, registering a year-on-year growth of 200.71 per cent. Net revenue of the company rose substantially by 25.44 per cent at Rs 35.35 crore in October-December quarter of this fiscal as against Rs 28.18 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 17.68 per cent to Rs 28.62 crore from Rs 24.32 crore in year ago period. Other Income grew by 818.18 per cent at Rs 2.02 crore versus (Dec'16 Rs 0.22 crore). Operating Profit surged by 31.19 per cent to Rs 6.73 crore as against Rs 5.13 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 4.62 per cent in December quarter. Interest declined by 17.24 per cent y-o-y to Rs 1.20 crore, while Taxation increased by 94.67 per cent at Rs 1.46 crore (Dec'16 Rs 0.75 crore).

16-02-2018 18:52

DIC India posts Q4 net loss of Rs 3.51 cr

The company reported standalone net loss during the quarter stood at Rs 3.51 crore compared to net profit of Rs 5.12 crore in the previous year quarter. Net revenue of the company rose moderately by 11.52 per cent at Rs 199.54 crore in October-December quarter of this fiscal as against Rs 178.93 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 11.47 per cent to Rs 195.08 crore from Rs 175.01 crore in year ago period. Other Income dipped by 48.77 per cent at Rs 1.87 crore versus (Dec'16 Rs 3.65 crore). Operating Profit slipped by 8.23 per cent to Rs 4.46 crore as against Rs 4.86 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 17.34 per cent in December quarter. Interest declined by 13.48 per cent y-o-y to Rs 0.77 crore, while Taxation increased by 418.66 per cent at Rs -6.95 crore (Dec'16 Rs -1.34 crore).

16-02-2018 18:52

Varun Beverages posts Q4 net loss of Rs 69.08 cr

The company reported standalone net loss during the quarter stood at Rs 69.08 crore as compared to net loss of Rs 68.84 crore in the previous year quarter. Net revenue of the company rose substantially by 36.65 per cent at Rs 329.92 crore in October-December quarter of this fiscal as against Rs 241.44 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 23.91 per cent to Rs 322.91 crore from Rs 260.60 crore in year ago period. Other Income dipped by 99.09 per cent at Rs 0.27 crore versus (Dec'16 Rs 29.59 crore). Operating Profit surged by 154.22 per cent to Rs 7.01 crore as against Rs -12.93 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 139.81 per cent in December quarter. Interest grew by 40.03 per cent y-o-y to Rs 53.14 crore, while Taxation increased by 54.77 per cent at Rs -46.54 crore (Dec'16 Rs -30.07 crore).

16-02-2018 18:52

Jayshree Tea Q3 net profit zooms 8589.47% at Rs 16.51 cr

The company reported standalone net profit of Rs 16.51 crore for the quarter ended December 31, 2017 as compared to Rs 0.19 crore in the same period last year, registering a year-on-year growth of 8589.47 per cent. Net revenue of the company rose moderately by 20.00 per cent at Rs 202.33 crore in October-December quarter of this fiscal as against Rs 168.61 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 11.77 per cent to Rs 178.94 crore from Rs 160.10 crore in year ago period. Other Income grew by 39.32 per cent at Rs 5.74 crore versus (Dec'16 Rs 4.12 crore). Operating Profit surged by 142.13 per cent to Rs 23.39 crore as against Rs 9.66 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 101.75 per cent in December quarter. Interest declined by 12.02 per cent y-o-y to Rs 8.86 crore

16-02-2018 18:52

Rights: Indiabulls Ventures to issue 3 shares for every 16 held

Indiabulls Ventures, one of India's leading capital market companies, on Friday said that it will raise upto Rs 2,000 crore on a rights basis to the eligible equity shareholders of the company in the ratio of 3 rights equity shares for every 16 fully paid-up equity shares. “The company to issue upto 83,333,333 partly paid up equity shares of face value of Rs 2 each of Indiabulls Ventures for cash at a price of Rs 240 (including a premium of Rs 238) per equity share for an amount aggregating up to Rs 20,000 million on a rights basis to the eligible equity shareholders of the company in the ratio of 3 rights equity shares for every 16 fully paid-up equity shares held by such eligible equity shareholders on the Record Date, i.e. on February 12, 2018,” the company said in a filing to the Bombay Stock Exchange. Meanwhile, shares of company closed day’s trade at Rs 253.20 apiece, up 1.32 per cent, on the Bombay Stock Exchange on Friday.

16-02-2018 17:01

Ipca Laboratorie - Financial Result Updates

IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2017.

07-Feb-2018 12:47 PM

Ipca Laboratorie - Financial Results For The 3Rd Quarter And Nine Months Ended Dec 31, 2017

Financial Results for the 3rd Quarter and nine months ended Dec 31, 2017

07-Feb-2018 12:45 PM

Ipca Laboratorie - Analysts/Institutional Investor Meet/Con. Call Updates

IPCA Laboratories Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates.Kindly note that a Conference Call to discuss the Company''s Q3 FY18 earnings and business update will be held on Thursday, 8th February, 2018 at 11.00 hrs IST.

31-Jan-2018 02:38 PM

Ipca Laboratorie - Analyst / Investor Meet - Intimation

Kindly note that a Conference Call to discuss the Company's Q3 FY18 earnings and business update will be held on Thursday, 8th February, 2018 at 11.00 hrs IST.

31-Jan-2018 02:38 PM

Ipca Laboratorie - Board Meeting On 7Th February 2018

A meeting of the Board of Directors of the Company will be held on Wednesday, 7th February, 2018, inter-alia, to consider and take on record the Unaudited Financial Results for the 3rd quarter and nine months ended 31st December, 2017 of the financial year 2017- 18.

Further, with reference to the above meeting of the Board of Directors, the trading window for dealing in the securities of the Company by the insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed with immediate effect and till 9th February, 2018.

22-Jan-2018 10:36 AM

Ipca Laboratorie - Financial Results For The 3Rd Quarter And Nine Months Ended Dec 31, 2017

Financial Results for the 3rd Quarter and nine months ended Dec 31, 2017

07-Feb-2018 12:45 PM

Ipca Laboratorie - Analyst / Investor Meet - Intimation

Kindly note that a Conference Call to discuss the Company's Q3 FY18 earnings and business update will be held on Thursday, 8th February, 2018 at 11.00 hrs IST.

31-Jan-2018 02:38 PM

Ipca Laboratorie - Board Meeting On 7Th February 2018

A meeting of the Board of Directors of the Company will be held on Wednesday, 7th February, 2018, inter-alia, to consider and take on record the Unaudited Financial Results for the 3rd quarter and nine months ended 31st December, 2017 of the financial year 2017- 18.

Further, with reference to the above meeting of the Board of Directors, the trading window for dealing in the securities of the Company by the insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed with immediate effect and till 9th February, 2018.

22-Jan-2018 10:36 AM

Corporate Details

About Management

One of the first modern pharma factory of yesteryears was commissioned by Ipca at Mumbai in 1969. The company was originally promoted by a group of medical professionals and businessmen and was incorporated as 'The Indian Pharmaceutical Combine Association Limited.' in October 1949. The present management took over in November 1975 when the total turnover of the company was just Rs. 0.54 crores. Currently, this premise where Ipca started its operations, houses the Registered Office of the company. Key departments like International Marketing, R&D (Formulations) and Analytical Development Lab are located here. YEAR EVENTS 1949 - Ipca Laboratories Ltd. was incorporated on 19th October, in Mumbai, under the name `The Indian Pharmaceutical Combine Association Limited'. The Company manufacture pharmaceutical products such as tablets, capsules, vials and ampoules. The Company was promoted by a group of medical professionals viz., Dr. N.K. Chaina, Dr. A.M. Desai, Dr. N.S. Tibrawala, K.M. Shroff, S.F. Kirawal, U.H. Dalal and K.B. Mehla. 1964 - The name was subsequently changed to `Ipca Laboratories Ltd.' on 6th August 1964. The name was further changed to `Ipca Laboratories Private Limited' on 13th January 1966. The name of the company was again changed to `Ipca Laboratories Ltd.' on 9th August 1988. The company became a Public Limited Company on 24th March, 1993. 1975 - The management of the company was taken over by Amitabh Bachchan, Ajitabh Bachchan, Jaya Bachchan, M.R. Chandurkar, P.C. Godha. 1994 - The Company undertook to set up a modern plant at Athal, Silvassa, for manufacture of pharmaceutical formulations. Plant and machinery comprising blenders, auto tablet coaters, fluid bed dryers, etc., procured indigenously. The Tatlam bulk drug unit capacity was increased to 500 TPA. 1995 - 9,225,000 No. of equity shares allotted to promoters, friends, relatives and associates (of these, 225,000 were Rights shares at a premium of Rs 120 per share). During February, the Company issued 3,275,000 No. of equity shares of Rs 10 each at a premium of Rs 120 per share of which 150,000 shares reserved for allotment on a preferential basis to employees of the Company (all were taken up). Balance 3,125,000 shares issued to the public (all were taken up). 2002-R S Hugar, former managing director of Global Trust Bank, has joined the board of directors of Ipca as non-executive chairman with effect from June 11, 2002. 2003 -Launched new domestic marketing division, ACTIVA , dedicated to Rheumatology Care. First Company in India to have such division for marketing superspeciality molecules. - Launched new domestic marketing division,Hy Care dedicated to Cardio-Diabetology segments. - Wholly owned subsidiary `Ipca Pharmaceuticals Inc.' incorporated in United States of America. -Wholly owned subsidiary `Ipca Laboratories (UK) Ltd.' incorporated in United Kingdom. - Forbes, a leading US business magazine, selected among its top 200 successful, rising companies outside USA, with sales under USD 1 Billion. 2004 -Members of the Company have approved the amalgamation in the nature of merger of Innotech Pharma Ltd., a 100% subsidiary of the Company, with Company -Ipca Laboratories Ltd. unveils novel injectable antibiotic combination of cefotaxime sodium with sulbactam sodium for the first time in the country under the brand name 'Sultax' -Received 'Lifetime Achievement Award' for the year2002-03 from from CHEMEXIL (Basic Chemicals,Pharmaceuticals & Cosmetics Export Promotion Council)for export promotion over the years. -Commissioned new formulation plant at Silvassa -Forbes Asia, a leading US business magazine selected Ipca, for the second consecutive year as one among the first 200 'Best under a Billion Company' in Asia 2005 -Ipca Laboratories Ltd has informed that the Company has entered into a Joint Venture (JV) agreement with Chongqing Holley Holding Company Ltd of China. -Merger of Innotech Pharma Limited with Ipca Laboratories Limited in August, 2005. -Acquires Cardiac brand ISORDIL from Wyeth Limited. -Forbes Asia, a leading US business magazine selected Ipca, for the third consecutive year as one among the first 200 'Best under a Billion Company' in Asia. - Ipca Laboratories has given the Bonus in the Ratio of 1:1 2006 -Ipca Laboratories Enters into Strategic Alliance with Ranbaxy Pharmaceuticals Inc., for the US Market -Ipca Laboratories launches fixed dose ACT combination and stops manufacturing of single ingredient Oral Artemisinin derivatives. -Ipca's new plant at Dehradun commenced operation on 5th May, 2006 2007 -Ipca - Ranbaxy Alliance received U.S. FDA marketing approval for Atenolol Tablets -Ipca Laboratories granted US FDA approval for Hydroxychloroquine sulfate tablet -Ipca Laboratories - Acquisition of 100% shareholding of formulation dossier registration holding companies in Australia and N -Ipca launched eighth domestic marketing division, 'Altus' which caters to intensivists and surgeons. -Ipca has been awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, 2007. In the past, company has received same award for three consecutive years' 2003, 2004 and 2005. 2008 -Ipca Laboratories receives US FDA approval for Propranolol Hydrochloride Tablets -Tonira Pharma's Nandesari unit (API plant at Baroda) receives US-FDA approval. -Ipca Laboratories Ltd has re-appointed Mr. Premchand Godha as the Managing Director of the Company for a further period of 5 years w.e.f. April 01, 2008. -Ipca-Piparia, formulation manufacturing unit receives MHRA-UK approval. This is the 3rd plant after Athal and Kandla receiving this qualification. -WHO prequalify Ipca's dossier of ARTESUNATE + AMODIAQUINE Co Blister making Ipca the 2nd company in the world and the first Indian company to receive this prequalification. 2009 -Ipca received Best Patent Award during the year 2007 - 08 2010 - Ipca Laboratories Ltd has informed that the Board of Directors of the Company at its meeting held on January 21, 2010, inter alia, appointed Mr. Anand T Kusre as a Director of the Company. -Company has splits its Face value of Shares from Rs 10 to Rs 2 2011 -Ipca Laboratories has received approval from UK Medicines and Healthcare Products Regulatory Agency for its fourth manufacturing unit at a Special Economic Zone in Indore for good manufacturing practices under the regulator. -Ipca labs bags nod to amalgamate Tonira Pharma 2012 -Mr. Dev Parkash Yadava has been appointed as an Additional Director of the Company -IPCA Laboratories bags USFDA nod Indore formulations manufacturing facility 2013 -IPCA received Corporate Citizen Award' for best corporate governance practice. -IPCA Dehradun won the "Energy Conservation" Award for the 3rd year in a row. -IPCA featured on the 8th position in the list of 'India's Most Admired Companies, in a survey carried out by Fortune India, in collaboration with The Hay Group, for the second time. -IPCA Laboratories said that SEZ Indore formulations manufacturing unit has been found acceptable after the inspection of US-FDA. 2014 -IPCA Laboratories "Acquisition of High Potency Oral Solid Dosage formulations manufacturing unit situated at Pithampur near Indore". -IPCA has entered into an alliance with Oncobiologics, Inc. USA for the development, manufacture and commercialization of biosimilar monoclonal antibody products. -IPCA Sports Club wins the E-Merck Inter-Pharma Cricket Tournament. -IPCA acquires formulations manufacturing unit located at Tarapur, Dist. Palghar, Maharashtra. -IPCA Sports Club wins Dreamz Trophy (T-20 & 40-overs format). -New product Launch - Pacimolr Active -Whistle Blower Policy implemented. 2016 -Ipca Lab wins Clinical and Research Excellence (CARE) awards. -Ipca was awarded by 'Indian Drug Manufacturers Association (IDMA) Best Formulation Patent (2014-15)' for its formulation patent of Hydroxychloroquine and its combinations in treatment of Diabetes Mellitus at 54th IDMA annual day celebration held on 23rd January 2016. -Ipca Laboratories wins the 'Clinical Trial result of the year' at the first annual CARE Award held at Boston, USA on 27th April 2016. -Ipca's Ratlam manufacturing Unit won 1st prize in National Energy Conservation Award 2016. This ceremony was hosted in Delhi on 14th December 2016. -Ipca Laboratories has been conferred with "Intellectual Property (IP) Excellence Award 2016" for adopting "The Best Practices in IP Intelligence" in a function organized in Mumbai on November 28th, 2016.

Registered Office

Village Ranu, (Taluka Padra),

2662-227300,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.